Navigation Links
Glenmark Wins Two Prestigious Global Recognitions at SCRIP Awards 2011
Date:11/4/2011

MUMBAI, India, November 4, 2011 /PRNewswire/ --

SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with two global recognitions, for its business excellence and innovative R & D capabilities. At a glittering ceremony in London which was attended by the Who's Who of the world pharmaceutical industry on November 3; Glenmark was presented with 'Best Company in Emerging Markets' & 'Best Overall Pipeline' recognitions for the year 2011.

"On behalf of our 8000 employees worldwide, we are honoured to receive two prestigious distinctions from a reputed organisation like Informa Healthcare, which hosts the SCRIP Awards," said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Limited, who received the awards on behalf of the company.  "We are specially delighted at having bagged the 'Best Overall Pipeline' distinction which is a testimony of our world-class R&D capabilities and an enormous tribute to all our research staff around the world who have committed themselves over many years to the development of our innovative pipeline," he added.

For SCRIP Awards 2011, Glenmark was the only company worldwide to be shortlisted under four categories. 'Executive of the Year - Glenn Saldanha' and 'Licensing Deal of the Year - GBR 500' were the other 2 categories, where Glenmark was nominated for this year's awards.

While announcing the nominations for Glenmark; SCRIP magazine commented:

  • "Glenmark is a leader among the emerging market companies in drug discovery and development and most of its active substances in the pipeline are first-in-Class." *1
  • "Glenmark's achievements over the year included a major deal with Sanofi in Crohn's disease, completing Phase III trials of its first novel product, crofelemer and demonstrated higher sales and profit growth."*2

* 1 SCRIP magazine issue dated Sep 23, 2011  * 2 SCRIP magazine issue dated Sep 16, 2011

About Glenmark

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India.  It is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity).  Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis, IBD, etc.] and Pain [neuropathic pain and inflammatory pain].


'/>"/>
SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pars Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R)
2. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. COPAN WASP® Lands at Prestigious Boston Medical Center
5. NxStage Board Member Dr. Barry M. Straube Honored with Prestigious Award from the American Association of Kidney Patients
6. Portrait Plasma Skin Regeneration Resurfaces at Prestigious Symposium
7. ITelagen Named to Prestigious 2011 Inc. 5000 List of Fastest-Growing Companies
8. Upsher-Smith Receives Prestigious DIANA Award for Third Year in a Row
9. Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility
10. Luminex Corporation Wins Prestigious Medical Design Excellence Award
11. Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets ... Market Size & Forecast By Type (Insource IONM, Outsource IONM), ... report to their offering. ... The global Intraoperative Neuromonitoring (IONM) market ... intraoperative neuromonitoring market is anticipated to witness significant growth in ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... ... aesthetic devices market to grow at a CAGR of 8.12% during ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:3/29/2017)... 29, 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused ... today announced that Carmine N. Stengone , president and chief ... Needham & Company 16 th Annual Healthcare Conference on Wednesday, ... the Westin Grand Central Hotel in New York City ... ...
Breaking Medicine Technology:
(Date:3/30/2017)... Philadelphia, PA (PRWEB) , ... March 30, 2017 ... ... Wharton School is expanding its educational offerings of corporate finance programs to address ... a new program, will help executives increase their knowledge of sophisticated corporate finance ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ” with noted ... 1:00 pm ET. This conference discusses strategies to prevent readmissions in light of ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... MD (PRWEB) , ... March 30, 2017 , ... CHARM ... Charm City Run has announced that Mercy Medical Center will serve as the official ... the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk or ...
(Date:3/29/2017)... ... 2017 , ... Wells Pharmacy Network, a proud A4M Platinum ... World Congress, in Hollywood Florida April 6-8, 2017. , Ben David, CEO of ... in the training of physicians, scientists, and members of the public on anti-aging ...
Breaking Medicine News(10 mins):